Fibrocell Science to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on March 17

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that it will report fourth quarter and full-year 2013 financial results and provide an update on the morning of March 17, 2014. The update will include its collaboration with Intrexon Corporation (NYSE:XON). David Pernock, chairman and chief executive officer of Fibrocell, will host the conference call and webcast at 8:30 a.m. EDT, Mar. 17, 2014.